FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:316-318 February 1, 1996 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Many pharmacologic advances involve creating compounds that bind and disable proteins. Such compounds include propranolol, which blocks the -adrenergic receptor; cimetidine, which blocks the H₂ receptor; calcium-channel blockers; angiotensin-converting–enzyme inhibitors; and inhibitors of the H+/K+–ATPase pump. A new way to block protein function is to prevent the translation of messenger RNA (mRNA) into protein.

If the nucleic acid sequence encoding a protein is known, molecules can be designed to bind the corresponding mRNA, thereby inhibiting the production of the protein (Figure 1). The nucleotide sequence of DNA or RNA that contains the information for the amino acid sequence . . . [Full Text of this Article]

Source Information

From the Division of Gastroenterology, Department of Internal Medicine, University of Michigan School of Medicine, and the Ann Arbor Veterans Affairs Medical Center, Ann Arbor, Mich.

Address reprint requests to Dr. McDonnell at 111D Internal Medicine, Ann Arbor Veterans Affairs Medical Center, 2115 Fuller Rd., Ann Arbor, MI 48105.

Recommended Reading

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.